奇正藏藥(002287.SZ):計劃在拉薩建設區域總部基地-德堂林家園
格隆匯9月24日丨奇正藏藥(002287.SZ)公佈,公司位於拉薩區域的辦公樓目前已經處於飽和狀態,在藏子公司及銷售團隊的辦公用場地緊張,已經不能滿足公司需求。根據公司發展規劃,公司計劃在拉薩建設區域總部基地——德堂林家園項目(“德堂林家園”), 項目實施主體為奇正藏藥,項目總投資擬為5億元人民幣,該項目為集研發創新平台、企業文化展示、辦公、藏醫特色康復及健康管理、藏藥材展示交易、專家及員工公寓為一體的基礎設施建設,為公司自建自用項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.